AZ hopes biotech spirit will help fund promising pipeline
AstraZeneca will behave as a biotech and “externalise” its business model to get maximum value from its promising pipeline.
Read MoreAuthor: Kevin Grogan
King’s Fund laments ‘disastrous’ NHS reforms
Health think tank the King’s Fund has issued a scathing attack on the government’s stewardship of the NHS, particularly the Health and Social Care Bill.
Read MoreMargaret Hamburg to step down as head of FDA
Tributes have been flooding in for Margaret Hamburg after she confirmed that she is stepping down as commissioner of the US Food and Drug Administration.
Read MorePfizer to buy Hospira in $17 billion deal
Cash-rich Pfizer is splashing out some $17 billion to buy Hospira and become a leading player in the biosimilars market.
Read MoreGSK hopes for happier times as earnings fall
GlaxoSmithKline has ended a disappointing year with another set of mediocre figures for the fourth quarter but the drugs giant is hopeful it is on the right track.
Read More- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
